| 1.1099 0.02 (1.83%) | 05-23 11:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.63  |
1-year : | 8.35 |
| Resists | First : | 4.82 |
Second : | 7.15 |
| Pivot price | 2.79 |
|||
| Supports | First : | 1.05 | Second : | 0.88 |
| MAs | MA(5) : | 1.19 |
MA(20) : | 3.07 |
| MA(100) : | 4.49 |
MA(250) : | 6.15 |
|
| MACD | MACD : | -1.1 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 0.9 |
D(3) : | 1.9 |
| RSI | RSI(14): 26.7  |
|||
| 52-week | High : | 16.25 | Low : | 1.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAOV ] has closed above bottom band by 21.2%. Bollinger Bands are 70.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.19 - 1.2 | 1.2 - 1.21 |
| Low: | 1.04 - 1.05 | 1.05 - 1.06 |
| Close: | 1.08 - 1.09 | 1.09 - 1.1 |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Tue, 20 May 2025
NanoVibronix, Inc. SEC 10-Q Report - TradingView
Fri, 16 May 2025
NanoVibronix Announces Closing of $10 Million Public Offering of Preferred Stock and Warrants - Business Wire
Wed, 14 May 2025
NanoVibronix Announces Closing of $10 Million Public Offering of Preferred Stock and Warrants | NAOV Stock News - GuruFocus
Mon, 12 May 2025
NanoVibronix Announces Results from UroShield™ Case Series - Stock Titan
Thu, 01 May 2025
NanoVibronix (NAOV) Achieves Nasdaq Compliance, Ensures Continued Listing - GuruFocus
Fri, 11 Apr 2025
NanoVibronix secures $360K note, meets Nasdaq compliance - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 2 (%) |
| Shares Short | 110 (K) |
| Shares Short P.Month | 39 (K) |
| EPS | -151.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.64 |
| Profit Margin | -144.9 % |
| Operating Margin | -308.6 % |
| Return on Assets (ttm) | -43.5 % |
| Return on Equity (ttm) | -160.6 % |
| Qtrly Rev. Growth | -62.3 % |
| Gross Profit (p.s.) | 1.82 |
| Sales Per Share | 3.1 |
| EBITDA (p.s.) | -4.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.66 |
| Price to Sales | 0.35 |
| Price to Cash Flow | -0.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|